



Review

# Systematic Review of the Epidemiological Burden of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Across Europe: Current Evidence and EUROMENE Research Recommendations for Epidemiology

Fernando Estévez-López <sup>1,\*</sup>, Kathleen Mudie <sup>2,†</sup>, Xia Wang-Steverding <sup>3,‡</sup>, Inger Johanne Bakken <sup>4</sup>, Andrejs Ivanovs <sup>5</sup>, Jesús Castro-Marrero <sup>6</sup>, Luis Nacul <sup>2</sup>, Jose Alegre <sup>6</sup>, Paweł Zalewski <sup>7</sup>, Joanna Słomko <sup>7</sup>, Elin Bolle Strand <sup>8,9</sup>, Derek Pheby <sup>10</sup>, Evelina Shikova <sup>11</sup>, Lorenzo Lorusso <sup>12</sup>, Enrica Capelli <sup>13</sup>, Slobodan Sekulic <sup>14</sup>, Carmen Scheibenbogen <sup>15</sup>, Nuno Sepúlveda <sup>2,16</sup>, Modra Murovska <sup>17,†</sup> and Eliana Lacerda <sup>2,†,§</sup> on behalf of The European Network on ME/CFS (EUROMENE)

- <sup>1</sup> Department of Child and Adolescent Psychiatry/Psychology, Erasmus MC University Medical Center, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands
  - <sup>2</sup> Department of Clinical Research, Faculty of Infectious & Tropical Disease, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK; Kathleen.Mudie1@lshtm.ac.uk (K.M.); Luis.Nacul@lshtm.ac.uk (L.N.); Nuno.Sepulveda@lshtm.ac.uk (N.S.); Eliana.Lacerda@lshtm.ac.uk (E.L.)
  - <sup>3</sup> Warwick Medical School, University of Warwick, Coventry CV4 7HL, UK; xiasteverding@gmail.com
  - <sup>4</sup> Centre for Fertility and Health (CeFH), Norwegian Institute of Public Health, 0456 Oslo, Norway; Inger.Johanne.Bakken@helseidir.no
  - <sup>5</sup> Statistics Unit, Riga Stradins University, LV-1007 Riga, Latvia; Andrejs.Ivanovs@rsu.lv
  - <sup>6</sup> ME/CFS Unit, Division of Rheumatology, Vall d'Hebron Hospital Research Institute (VHIR), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain; jesus.castro@vhir.org (J.C.-M.); jalegre@vhebron.net (J.A.)
  - <sup>7</sup> Department of Hygiene, Epidemiology, Ergonomics and Postgraduate Education, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-094 Bydgoszcz, Poland; p.zalewski@cm.umk.pl (P.Z.); jslomko@cm.umk.pl (J.S.)
  - <sup>8</sup> Faculty of Health Studies, VID Specialized University, 0370 Oslo, Norway; Elin.Bolle.Strand@vid.no
  - <sup>9</sup> Norway & National Advisory Unit on CFS/ME, Oslo University Hospital, 0424 Oslo, Norway
  - <sup>10</sup> Faculty of Health and Society, Buckinghamshire New University, High Wycombe HP11 3JZ, UK; derekpheby@btinternet.com
  - <sup>11</sup> Department of Virology, National Center of Infectious and Parasitic Diseases, Sofia, Bulgaria & The National Specialized Hospital for Active Treatment in Haematological Diseases, 1233 Sofia, Bulgaria; evelina\_sh@abv.bg
  - <sup>12</sup> Neurology Department, ASST-Lecco, 23807 Merate, Italy; lorusso.lorenzo@gmail.com
  - <sup>13</sup> Department of Earth and Environmental Sciences and Centre for Health Technologies, University of Pavia, 27100 Pavia, Italy; enrica.capelli@unipv.it
  - <sup>14</sup> Department of Neurology, Medical Faculty Novi Sad, University of Novi Sad, 21000 Novi Sad, Serbia; slobodan.sekulic@mf.uns.ac.rs
  - <sup>15</sup> Institute for Medical Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany; Carmen.Scheibenbogen@charite.de
  - <sup>16</sup> Centre of Statistics and Its Applications, University of Lisbon, 1749-016 Lisbon, Portugal
  - <sup>17</sup> Institute of Microbiology and Virology, Riga Stradins University, LV-1007 Riga, Latvia; modra@latnet.lv
- \* Correspondence: fer@estevez-lopez.com
- † These authors have contributed equally as the senior authors.
- ‡ These authors have contributed equally as the second authors.
- § The European Network on ME/CFS (EUROMENE) is provided in the Acknowledgments.

Received: 9 April 2020; Accepted: 19 May 2020; Published: 21 May 2020



**Abstract:** This review aimed at determining the prevalence and incidence of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) in Europe. We conducted a primary search in Scopus, PubMed and Web of Science for publications between 1994 and 15 June 2019 (PROSPERO: CRD42017078688). Additionally, we performed a backward-(reference lists) and forward-(citations) search of the works included in this review. Grey literature was addressed by contacting all members of the European Network on ME/CFS (EUROMENE). Independent reviewers searched, screened and selected studies, extracted data and evaluated the methodological and reporting quality. For prevalence, two studies in adults and one study in adolescents were included. Prevalence ranged from 0.1% to 2.2%. Two studies also included incidence estimates. In conclusion, studies on the prevalence and incidence of ME/CFS in Europe were scarce. Our findings point to the pressing need for well-designed and statistically powered epidemiological studies. To overcome the shortcomings of the current state-of-the-art, EUROMENE recommends that future research is better conducted in the community, reviewing the clinical history of potential cases, obtaining additional objective information (when needed) and using adequate ME/CFS case definitions; namely, the Centers for Disease Control & Prevention–1994, Canadian Consensus Criteria, or Institute of Medicine criteria.

**Keywords:** central nervous system diseases; infections; muscular diseases; post-exertional malaise; virus diseases

---

## 1. Introduction

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a disease characterised by post-exertional malaise, including persistent fatigue, and other symptoms aggravated by physical or cognitive efforts, at intensities previously well tolerated by the individual. Post-exertional symptoms may be experienced immediately or, more typically, may be delayed for hours, days, or even longer. They are associated with slow recovery, which may extend to one or more days, together with a heterogeneous array of other symptoms that may include musculoskeletal pain, sleep disturbances, and impaired cognition, among many others [1–4]. Thus, ME/CFS often decreases health-related quality of life, and affects employment, and the social and familial relationships of patients [5–9]. Although it is unclear whether ME and CFS are two different diseases [10], we will pragmatically use the term ME/CFS.

An additional common burden for patients and their families is lack of recognition of ME/CFS as a serious disease in various countries [6,11]. This lack of official recognition could be explained by poor knowledge of the disease on the parts of different health-related stakeholders. In addition, symptoms often fluctuate over time in the same patient. Also, the use of different definitions for the disease could lead to the production of estimates of ME/CFS prevalence and incidence which are not directly comparable, even in the same population [12]. For example, the prevalence of ME/CFS in Iceland was estimated at between 0 and 5% using two different but widely accepted case definitions [13]. Thus, the real burden of ME/CFS across populations remains elusive, and is a matter of controversial debate.

Previous systematic reviews on the prevalence and incidence of ME/CFS included studies from many parts of the world [14–18]. However, most of these reviews were conducted some years ago [14–17]. In addition, they neither reported the incidence of ME/CFS nor included children or adolescents [14–18]. Also, the reviews were not easily comparable, due to the use of different case definitions for ME/CFS. The quality of reporting was not adequately evaluated in most of these reviews, even in the most recent study [18]. Most importantly, none of these previous reviews focused on the epidemiology of ME/CFS in Europe. The European Epidemiological Study for ME/CFS (Euro-EpiME), from the European Network on ME/CFS (EUROMENE, EU-funded COST Action; Reference number: 15111) is intended to fill this knowledge gap by performing a systematic review of epidemiological data on ME/CFS in Europe.

Therefore, the aim of the present systematic review was to determine the prevalence and incidence of ME/CFS in Europe and to overcome the shortcomings of the previous reviews.

## 2. Methods

### 2.1. General Information Concerning the Systematic Review

The present literature review is in accordance with the PRISMA framework for systematic reviews and meta-analyses [19]. The design of the present work was fully specified in advance. It was registered in the PROSPERO database with the registration number CRD42017078688. Further details on the protocol can be found elsewhere [20]. This protocol was subject to minor amendments, agreed at a EUROMENE meeting. A description of the amendments can be found in Table A1. This was made publicly available before conducting the primary electronic search at [http://www.euromene.eu/workinggroups/20190604protocol-amendments\\_prevalence-me-cfs.pdf](http://www.euromene.eu/workinggroups/20190604protocol-amendments_prevalence-me-cfs.pdf).

#### 2.1.1. Inclusion Criteria

- Studies reporting either prevalence or incidence of ME/CFS, irrespective of age group, utilizing any of the following clinical diagnostic criteria: Centers for Disease Control & Prevention (CDC)–1994 [1], Canadian Consensus Criteria [21], London Criteria [22], International Consensus Criteria [2], or Institute of Medicine criteria [3].
- Studies from European countries; namely (by alphabetical order), Albania, Andorra, Armenia, Austria, Azerbaijan, Belarus, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czechia, Denmark, Estonia, Finland, France, Georgia, Germany, Greece, Hungary, Iceland, Ireland, Italy, Kazakhstan, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Malta, Moldova, Monaco, Montenegro, the Netherlands, North Macedonia (formerly Macedonia), Norway, Poland, Portugal, Romania, Russia, San Marino, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine, the United Kingdom and Vatican City.
- Studies conducted in community or primary care settings.

#### 2.1.2. Exclusion Criteria

- Studies without primary data (e.g., reviews).
- Studies conducted in selected samples (e.g., post-infection, following vaccination or in high-risk population sub-groups such as war veterans).
- Studies based on self-reported diagnosis of ME/CFS.
- Studies with definitions inappropriate for the purposes of the present review (e.g., CFS-like illness or other clinical criteria, such as the Oxford criteria, due to lack of specificity [23]).
- Duplicate reports. When populations are overlapping, the study with the largest sample size was included.
- Studies published before 1994, when the first case definition of ME/CFS of those included in the present work was launched; namely, CDC–1994 [1].

No language restriction was applied.

### 2.2. Search Strategy for Identifying Relevant Studies

The search strategy consisted of two stages.

Firstly, a primary systematic literature search in three electronic databases was performed by two independent reviewers (F.E.-L. and K.M.) on 15 June 2019. The combination of search terms in each database was:

- Scopus: ((epidemiology) OR {prevalence} OR {incidence}) AND ((chronic fatigue syndrome) OR {myalgic encephalomyelitis} OR {CFS/ME})

- PubMed: (“Fatigue Syndrome, Chronic”(Mesh) AND (“Incidence”(Mesh) OR “Epidemiology”(Mesh) OR “epidemiology” (Subheading)) OR “Prevalence”(Mesh) OR “Cross-Sectional Studies”(Mesh))
- Web of Science: (“epidemiology” OR “prevalence” OR “incidence”) AND (“chronic fatigue syndrome” OR “myalgic encephalomyelitis” OR “CFS/ME” OR “ME/CFS”)

Secondly, a complementary search was conducted as follows (i) a backward (by checking reference lists) and forward (by checking citations) search of the works included in the present review (F.E.-L.) and (ii) grey literature was addressed by contacting – via email - all the members of EUROMENE and asking them to provide, if available, prevalence rates, incidence rates or both of ME/CFS, in their countries, according to national registers, publications in their own languages, or any other publicly accessible source (J.C.-M.).

### 2.3. Selection of Studies for Inclusion to the Review

Two independent researchers (F.E.-L. and K.M.) screened records retrieved by the electronic search by titles/abstracts or by full text of works, to identify potential studies and their suitability. When disagreements emerged, consensus was obtained through discussion.

### 2.4. Assessment of Methodological Quality and Reporting of Data

The methodological quality of the eligible studies was evaluated with the Joanna Briggs Institute-Checklist for Prevalence Studies [24]. Before applying it, six members of the research team (i.e., F.E.-L., L.N., J.A., S.S., M.M., and E.L.) developed an agreed appraisal of the tool. The reporting quality of the eligible studies was evaluated using the observational studies in epidemiology (STROBE) checklist [25]. Two researchers evaluated independently the methodology (i.e., F.E.-L. and I.J.B.) and the quality of reporting (i.e., F.E.-L. and X.W.-S.) of the selected studies. When disagreements emerged between these two researchers, consensus was obtained through discussion.

### 2.5. Data Extraction and Management

To manage the selected studies, we used the Mendeley Desktop. Two researchers (F.E.-L. and A.I.) compiled independently the reference for each study (authors and year of publication), country, total sample size ( $n$  and % of women), age range, setting (e.g., primary care), case definition (i.e., diagnosis criteria), prevalence and/or incidence rates, overall and stratified by gender and age group (where available). When disagreements emerged between these two researchers, consensus was obtained through discussion.

### 2.6. Data Synthesis and Analysis

We anticipated that studies reporting the prevalence and incidence of ME/CFS in different European countries would be scarce [20]. This was confirmed after data selection. We therefore decided to provide a narrative (descriptive) rather than quantitative synthesis.

## 3. Results

In line with the Open Science framework, and for the sake of transparency and reproducibility, the metadata downloaded (BibTex-Files) from Scopus, PubMed and Web of Science, and which were imported into the Mendeley Desktop, are available in file S1. Figure 1 shows that the (primary) systematic literature search in three electronic databases yielded 2348 studies after automatic identification and deletion of duplicates by Mendeley (for the full list of studies, see supplementary file S2), from which 43 studies were screened in full text; (see supplementary file S3 for the rationale to exclude 40 studies). Three studies were included for prevalence [13,26,27]. Two of these studies also reported incidence estimates of ME/CFS [26,27]. The complementary search did not yield any additional articles.




Figure 1. Flow diagram for study selection. Notes. WOS, web of science.

Tables 1 and 2 show the characteristics of the included studies for prevalence and for incidence of ME/CFS, respectively, in European countries. Two of the studies were conducted in the United Kingdom [26,27] and the other in Iceland [13]. The sample sizes ranged from 842 [27] to 143,153 participants [26]. All studies used the CDC–1994 case definition [13,26,27] and one also used an additional case definition (namely, CCC–2003) in the same sample [26]. The target population in two studies was adults [13,26] while another study targeted adolescents [27]. The prevalence estimates ranged from 0.1% [27] to 2.2% [13]. In the two studies conducted in the United Kingdom, the estimated incidence rate was 15 cases per 100,000 adults per year [26] and 5 cases per 1000 adolescents per 6 months [27].

The methodology (Table 3) and the quality of reporting (Table A2) of the included studies were judged as good overall according to our appraisal tools. It should be noted that the prevalence estimates from Iceland had typographical errors in the original publication [13], as amended and communicated by the authors [28]. In this review, we used the amended figures [28].

**Table 1.** Characteristics of the included studies reporting point prevalence of ME/CFS in European countries.

| Reference           | Procedure   | Settings, Country                | Sample, Total (% Women) | Age Range                       | Case Definition      | Prevalence Estimate % (95% CI)             | Prevalence Estimate by Gender  |
|---------------------|---|----------------------------------|-------------------------|---------------------------------|----------------------|--|--|
| Nacul et al., [26]  | Electronic search (GPs databases), queries to GPs, clinical review of cases | Primary care, The United Kingdom | 143,000 (51%)           | Adults, 18 to 64 years old      | CDC–1994<br>CCC–2003 | 0.20 (0.18 to 0.23)<br>0.10 (0.09 to 0.12) | Women = 0.31 (0.27 to 0.35)<br>Men = 0.08 (0.06 to 0.10)<br>Women = 0.18 (0.15 to 0.21)<br>Men = 0.04 (0.03 to 0.06) |
| Lindal et al., [13] | Postal delivery to randomly selected people                                 | Community, Iceland               | 2471 (57%)              | Adults, 19 to 75 years old      | CDC–1994             | 2.2 (not reported)                         | Women = 3.0% (not reported)<br>Men = 1.1% (not reported)   |
| Rimes et al., [27]  | Random selection from the Child Benefit Register                            | Community, The United Kingdom    | 842 (not reported)      | Adolescents, 11 to 15 years old | CDC–1994             | 0.1 (not reported)                         | Not reported   |

Notes. The design of all included studies was cross-sectional. Figures are presented as accurate (i.e., number of decimals) as reported in the original publication. CCC, Canadian Consensus Criteria; CDC, Centers for Disease Control and Prevention; CI, Confidence Interval; GPs, General Practitioners.

**Table 2.** Characteristics of the included studies reporting the incidence of ME/CFS in European countries.

| Reference          | Follow-up, Procedure   | Settings, Country                | Sample, Total (Women, %) | Age Range                       | Case Definition      | Incidence Estimate  | Incidence Estimate by Gender  |
|--------------------|--|----------------------------------|--------------------------|---------------------------------|----------------------|---|---|
| Nacul et al., [26] | 12 months, Electronic search (GPs databases), queries to GPs, clinical review of cases | Primary care, The United Kingdom | 143,153 (51%)            | Adults, 18 to 64 years old      | CDC–1994<br>CCC–2003 | 15 new cases per 100,000 adults per year<br>5 new cases per 100,000 adults per year | Women = 23 new cases per 100,000 adults per year<br>Men = 7 new cases per 100,000 adults per year<br>Women = 6 new cases per 100,000 adults per year<br>Men = 3 new cases per 100,000 adults per year |
| Rimes et al., [27] | 4 to 6 months, random selection from the Child Benefit Register                        | Community, The United Kingdom    | 842 (not reported)       | Adolescents, 11 to 15 years old | CDC–1994             | 5 new cases per 1000 adolescents per 6 months                                       | Not reported  |

Notes. Figures are presented as accurate (i.e., number of decimals) as reported in the original publication. CCC, Canadian Consensus Criteria; CDC, Centers for Disease Control and Prevention; GP, General Practitioners.



**Table 3.** The methodological quality of the included studies evaluated by the Joanna Briggs Institute-Checklist for Prevalence Studies.

|   | Nacul et al.,<br>[26] | Lindal et al.,<br>[13] | Rimes et al.,<br>[27] |
|---|-----------------------|------------------------|-----------------------|
| 1. Appropriate sample frame                       | Yes                   | Yes                    | Yes                   |
| 2. Participants were sampled appropriately        | Yes                   | Yes                    | Yes                   |
| 3. Adequate sample size                           | Yes                   | Yes                    | Yes                   |
| 4. Participants and settings were well described  | Yes                   | Yes                    | Yes                   |
| 5. Data analysis with sufficient coverage         | Yes                   | No/Unclear             | Yes                   |
| 6. Valid methods for identifying the condition    | Yes                   | No/Unclear             | Yes                   |
| 7. Standard and reliable measure of the condition | Yes                   | Yes                    | Yes                   |
| 8. Appropriate statistical analyses               | Yes                   | Yes                    | Yes                   |
| 9. Adequate response rate                         | Yes                   | Yes                    | No/Unclear            |

#### 4. Discussion

Only three papers on ME/CFS prevalence [13,26,27] in Europe were included in this review. Two of these studies were conducted in the United Kingdom [26,27]. The prevalence estimates from Europe appear to be in the same range as those from other continents [29,30]. The current review shows that in Europe only two studies have aimed at estimating the incidence of ME/CFS, one in adults [26] and the other in adolescents [27]. Previous systematic reviews on the epidemiological burden of ME/CFS did not investigate the incidence of ME/CFS [14–17]. Overall, as expected [20], studies on prevalence and incidence of ME/CFS in Europe were scarce.

Among the included studies in adults using the CDC–1994 case definition, prevalence estimates ranged from 0.2% [26] to 2.2% [13]. Previous systematic reviews found a similar range of prevalence estimates in other continents. For instance, in the United States [16], estimates of ME/CFS prevalence ranged from 0.2% [29] to 2.5% [30]. As suggested previously [26], these large variations in estimates may be a consequence of differences in methods, in inclusion/exclusion criteria, and in case definitions of ME/CFS. For instance, if in the present review a wider range of case definitions for ME/CFS were included, the maximum estimation among the included studies would have been a prevalence estimate of 7.8% in Iceland, using the Lloyd definition [13]. This reflects the necessity of using standardised case definition in epidemiological studies of ME/CFS. In comparison with prevalence, the study of incidence in adults was even scarcer, as is indicated by the inclusion of only one study in the present systematic review [26].

Only one of the studies included was conducted in young people [27]. The prevalence estimate was found to be 0.1% in adolescents from 11 to 15 years old, and the incidence was estimated at 5 new cases per 1000 adolescents per 6 months [27]. While previous reviews have focused on adults [14,17], it is important to highlight that children and adolescents are also significantly affected by ME/CFS. Indeed, case definitions of ME/CFS were first established for adults, and later extended to younger age groups, reflecting an initial lack of attention to the paediatric population. In our view, ME/CFS in younger individuals requires further investigation.

##### 4.1. Implications

One of the studies included in the present review found that initial diagnoses of ME/CFS made by General Practitioners (GPs) were usually inaccurate, which impacts the estimation of the prevalence of ME/CFS [26]. Potential reasons for misdiagnosis include limited knowledge of or inability to recognise ME/CFS, and lack of access for patients with severe ME/CFS symptoms to GPs or other healthcare professionals [31]. In Europe, many primary care professionals rarely or never diagnose ME/CFS, and this could lead to potential disease misclassification. A possible way to overcome this problem is to offer training on ME/CFS diagnosis, and to support healthcare from primary care physicians, which may help to decrease the time to diagnosis, and therefore be beneficial to patients [32]. Cultural reasons may also explain this finding of misclassification [26]. A study of cultural differences that

may be involved in the non-recognition of ME/CFS as a debilitating disease with high socio-economic impact in Europe would be highly desirable [9,33].

In the studies included in the present review, those conducted in adults independently used more than one case definition [13,26], while that in the child population did not do so [27]. Until one universal case definition is accepted in Europe, one approach of using several case definitions independently allows the performance of multiple comparisons (e.g., to stratify patients with ME/CFS) [17] and, thereby to provide a more comprehensive picture of the epidemiology of ME/CFS in Europe. Another approach is to use several case definitions sequentially, which has been done in a number of European clinical studies; e.g., [34–36]. However, this sequential approach has a number of important limitations for epidemiological purposes, further details of which have been provided elsewhere [17].

Currently, there is no accepted objective diagnostic test for ME/CFS (e.g., imaging or blood tests) but many case definitions are available (for a review, [17]). Therefore, the identification of acceptable objective markers of ME/CFS which can be utilised in epidemiological research in Europe is of very high priority. On this question, differences between ME/CFS cases and controls have been observed in the brain (structure, function, and metabolites), cognitive function and sleep function [37–39]. Associations between the occurrence of ME/CFS clinical symptoms, HHV-6, HHV-7 and B19 infection/co-infection reactivation, and increased expression levels of TNF- $\alpha$  and IL6 [40] have been observed, as well as alterations in the levels of infection markers of B19V [41] and EBV [42]. In addition, patients' levels of muscular strength, as measured by the handgrip test, are related to the severity of ME/CFS [43]. Thus, it seems advisable that future epidemiological studies on ME/CFS should include objective clinical measurements in addition to patient-reported outcome measures, which should be summarised in the final reports, to improve the reliability and comparability of studies. In this context, when needed, it is important to adapt and validate questionnaires to languages other than English.

#### 4.2. EUROMENE Research Recommendations for Epidemiology

The resources needed for epidemiological studies in ME/CFS tend to be costly, as, in the absence of specific biomarkers. As a result “caseness” must be ascertained by clinical history, symptomology and exclusion of other conditions. This approach requires clinicians and a battery of tests. Therefore, to determine the prevalence and incidence of ME/CFS in Europe, EUROMENE is making four overarching recommendations, as follows:

Firstly, research is best conducted by screening the community, instead of via primary care physicians, because this would help to minimise both selection and referral biases observed in clinical samples [26,27]. This screening may be done by means of the DePaul Symptom Questionnaire (DSQ) [44] or the United Kingdom ME/CFS Biobank Participant Questionnaire (UKMEBPQ) [45]. These two questionnaires were developed to enable comprehensive assessment of the signs of ME/CFS.

Secondly, if the study is conducted in community settings, we recommend that the clinical histories of potential cases identified in the community should be reviewed, in order to search for both key and additional ME/CFS symptoms. Key symptoms are persistent and include debilitation, exhaustion, post-exertional malaise, unrefreshing sleep, widespread musculoskeletal pain and cognitive dysfunction. Additional symptoms may involve a myriad of signs, including, but not limited to, orthostatic intolerance, over-sensitivity to stress or sensory stimuli, food intolerance, infection-immune like symptoms, symptoms of irritable bowel syndrome, weight loss or gain, symptoms of sicca, anxiety and depression. If the study is conducted in primary care settings, participating GPs should identify potential individuals with ME/CFS, using specific disease codes and excluding other diseases that could explain their symptoms. In the United Kingdom, for instance, as the National Health Service (NHS) has universal coverage and unified databases containing a wealth of data on the registered population, research in primary care can be considered population-based. Thus, missing cases and refusals can be accounted, by looking at the characteristics of population covered by participating GP practices. However, the GPs must be willing to participate in the research effort, which – despite being incentivised in the National Institute of Health Research (NIHR), does not always happen. For countries that have



health care models based on mixed providers (i.e., private and public health care providers) or without common databases for patient information, this approach would be even more challenging.

Thirdly, when required, there is a need to obtain additional objective information by means of a clinical assessment that may involve a general examination (e.g., signs of anaemia, jaundice, and gross assessment of levels of hydration and nutritional status), a specific examination covering main body systems (e.g., heart and circulation) and a directed examination targeted according to general health history general clinical examination, findings, and specific symptoms which are reported (e.g., blood test for identifying rheumatoid factor).

Fourthly, to confirm ME/CFS cases, the CDC–1994 [1], Canadian Consensus Criteria [21], or Institute of Medicine criteria [3] criteria are found acceptable by EUROMENE. Additionally, the use of several independent case definitions is advisable because this may provide a more comprehensive picture of the epidemiology of ME/CFS in Europe and enhance comparability between studies. People whose symptoms may be mostly or largely explained by other conditions (e.g., cancer, post-traumatic stress disorder or rheumatoid arthritis) should not be identified as ME/CFS cases. When the presence of other conditions does not explain most of the symptoms and signs observed, they may be considered as comorbidities (e.g., fibromyalgia, irritable bowel syndrome, and sicca syndrome) [46].

EUROMENE acknowledges that meeting these four overarching recommendations is not always feasible due to limitations of economic and human resources, particularly in the context of a lack of funding for ME/CFS research. Indeed, it should be noted that, given the current paucity of knowledge of the prevalence and incidence of ME/CFS in Europe, less accurate estimations provided by more feasible research are still of interest. This is so as long as participants are not identified through subject self-diagnosis, or self-report of having been previously diagnosed without further corroboration by the research team. For instance, the alternative of asking potential ME/CFS cases to provide clinical reports of ME/CFS diagnosis could help to exclude alternative pathologies. When possible, and to harmonise research in Europe, ME/CFS cases are best identified by at least one of the following three case definitions: the CDC–1994 [1], Canadian Consensus Criteria [21], or Institute of Medicine criteria [3].

An ambitious approach to be considered is the development of a collaborative effort with concomitant studies using the same protocols, being either performed or developed in different European countries. In this way, the different factors related to the health care settings for each population could be compared and considered in the analyses. These include for example, population coverage, refusals, and missing cases – such as those with severe symptoms - who are less likely to attend health services and are usually underrepresented in research [47].

#### 4.3. Limitations and Strengths

Although no language restrictions were applied, most of the retrieved works (93%) were published in English. All the members of EUROMENE were contacted to identify potential grey literature in their countries according to national registers, publications in their own languages, or any other publicly accessible source. Thus, though we are reasonably confident that all the information in other languages was retrieved, studies in languages other than English were not included. The small number of included studies may be considered as a limitation of the present review. It could be argued that including only studies using the CDC–1994 [1], Canadian Consensus Criteria [21], London Criteria [22], International Consensus Criteria [2], or Institute of Medicine criteria [3] case definitions was too restrictive. However, we find that this restrictive approach was a strength of the present study. For instance, including studies based on people's self-report of having ME/CFS or with an inappropriate case definition (e.g., CFS-like illness or other clinical criteria, such as the Oxford criteria which lack of specificity) would have permitted inclusion of more studies, but would also have resulted in unreliable estimates. For instance, in a study conducted in Poland, from 1400 participants who identified themselves as suffering disabling fatigue, only 69 people met the CDC–1994 case definition of ME/CFS [48]. Additional strengths are the carefully designed search strategy, and the timespan coverage. Also, this review was conducted and reviewed by experienced researchers who are members of EUROMENE, which highlights the credibility and reliability of the findings.

## 5. Conclusions

As we anticipated, the present systematic review shows that research on the epidemiological burden of ME/CFS in Europe is scarce. Only three studies have estimated ME/CFS prevalence, while incidence has been estimated in two. Potential causes of this paucity of knowledge may be due to a European lack of (i) official disease recognition, (ii) consensus over case definitions, or (iii) investment by funding agencies, among others. By evidencing the paucity of epidemiological data on ME/CFS in Europe, our findings point to the pressing need for well-designed and statistically powered epidemiological studies. These are paramount requirements for informing and addressing the healthcare needs of people with ME/CFS, as well as for providing reliable information in order to ascertain the burden of disease for the European community, including its socio-economic impact. To overcome the shortcomings of the current state-of-the-art, EUROMENE recommends that future research is better conducted in the community, reviewing the clinical history of potential cases, obtaining additional objective information (when needed) and using adequate ME/CFS case definitions; namely, the CDC–1994 [1], Canadian Consensus Criteria [21], or Institute of Medicine criteria [3].

**Supplementary Materials:** The following are available online at <http://www.mdpi.com/2077-0383/9/5/1557/s1>, File S1: Metadata, File S2: List of references after excluding duplicate reports, File S3: List of references excluding after screening the full-text.

**Author Contributions:** F.E.-L., J.C.-M., X.W.-S., M.M., and E.L. designed the review. F.E.-L. and K.M. independently performed a primary systematic literature search in three electronic databases. F.E.-L. conducted a complementary search; a backward- (by checking reference lists) and a forward- (by checking citations) search of the works are included in the present review. J.C.-M. searched grey literature by contacting—via email - all the members of EUROMENE to provide, if available, information from their countries according to national registers, publications in their own languages, or any other publicly accessible source. F.E.-L. and K.M. independently screened records retrieved by the electronic search by titles/abstracts or full text of works for identifying potential studies and assessing their suitability. F.E.-L., L.N., J.A., S.S., M.M., and E.L. developed an agreed appraisal utilising the Joanna Briggs Institute-Checklist for Prevalence Studies for evaluating the methodological and reporting quality of the included studies. F.E.-L. and X.W.-S. evaluated the methodological quality of the included works. F.E.-L. and I.J.B. evaluated the reporting quality of the included works. F.E.-L. and A.I. independently extracted the information from the included studies. F.E.-L., K.M., X.W.-S., M.M., and E.L. drafted the manuscript. F.E.-L., K.M., X.W.-S., I.J.B., A.I., J.C.-M., L.N., P.Z., J.S., E.B.S., D.P., J.A., C.S., E.S., L.L., E.C., S.S., N.S., M.M., and E.L. participated in face-to-face EUROMENE meetings where decisions were made and findings were discussed as well as revised and approved the final version of the manuscript. M.M. and E.L. are the chair and vice chair of the EUROMENE action, respectively. F.E.-L. is the leader of the EUROMENE working group on Epidemiology and guarantor of the review. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by the COST (Action CA 15111: The European Network on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome; EUROMENE), the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie [grant agreement no. 707404 to F.E.-L.], the Bulgarian National Science Fund (ДКООТ 01/9 to E.S.). The funders of the present study did not have any role in the design, decision to publish, or preparation of the protocol.

**Acknowledgments:** The protocol of the present systematic review was agreed in a EUROMENE meeting in Belgrade (Serbia) on 7 September 2017. Discussions about the findings were carried out in EUROMENE meetings in London (the United Kingdom) on 12 September 2018, Warsaw (Poland) on 4 April 2019, and Riga (Latvia) on 12 March 2020. We thank all the participants for their active participation and valuable suggestions.

**Conflicts of Interest:** The authors declare no conflict of interest, and the funders of individual researchers had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.

## Appendix A

Table A1 shows amendments to the protocol of the present systematic review, and their rationale. These amendments were made publicly available before conducting the primary electronic search at [http://www.euromene.eu/workinggroups/20190604protocol-amendments\\_prevalence-me-cfs.pdf](http://www.euromene.eu/workinggroups/20190604protocol-amendments_prevalence-me-cfs.pdf).

We would like to apologise for any inconvenience, Fernando Estévez-López, on behalf of the EUROMENE working group on Epidemiology.

**Table A1.** Amendments (and rationale) to the protocol of the present systematic review.

| Original Protocol   | Amendments (A) and Rationale (R)  |
|---|---|
| Section: The primary systematic literature search on electronic databases.<br>Text: Two independent reviewers (FE-L and JC-M) will perform a primary electronic search in PubMed, Scopus and Web of Science on 9 January 2018 | A: The search will be updated to include works published up to 15 June 2019.<br>R: Due to budget restrictions to cover the publication fee, it was decided to postpone the preparation of this work.  |
| Section: Exclusion criteria<br>Text: Studies published more than 10 years ago (i.e., before 2008).  | A: Studies published before 1994.<br>R: The decision lacked of a strong rationale and it was too restrictive. Given that studies that used the CDC–1994, Canadian Consensus Criteria, London Criteria, International Consensus Criteria or Institute of Medicine criteria will be considered, we will search for the literature that has been published from 1994, when the CDC–1994 were launched. |

Notes. The original protocol is accessible in the following link: <https://bmjopen.bmj.com/content/8/9/e020817.long>. The table shows the amendments to the Protocol manuscript by Estévez-López et al. in BMJ Open.

**Table A2.** The reporting quality of the included studies evaluated by the observational studies in epidemiology (STROBE) checklist.

|                                       | Nacul et al., [26] | Lindal et al., [13] | Rimes et al., [27] |
|---------------------------------------|--------------------|---------------------|--------------------|
| Title and abstract                    |                    |                     |                    |
| 1a. Indicate the study design         | Yes                | Yes                 | Yes                |
| 1b. Informative and balanced abstract | Yes                | Yes                 | Yes                |
| Introduction                          |                    |                     |                    |
| 2. Background/rationale               | Yes                | Yes                 | Yes                |
| 3. Objectives                         | Yes                | Yes                 | Yes                |

**Table A2.** *Cont.*

|  | <b>Nacul et al., [26]</b> | <b>Lindal et al., [13]</b> | <b>Rimes et al., [27]</b> |
|--|---------------------------|----------------------------|---------------------------|
| Methods  |                           |                            |                           |
| 4. Study design  | Yes                       | No/Unclear                 | No/Unclear                |
| 5. Setting   | Yes                       | Yes                        | No/Unclear                |
| 6a. Participants                                       | Yes                       | Yes                        | Yes                       |
| 7. Variables   | Yes                       | Yes                        | Yes                       |
| 8. Data sources/measurement                            | Yes                       | Yes                        | Yes                       |
| 9. Bias  | No/Unclear                | No/Unclear                 | No/Unclear                |
| 10. Study size   | Yes                       | No/Unclear                 | No/Unclear                |
| 12a. Statistics: description of all methods            | Yes                       | Yes                        | Yes                       |
| 12b. Statistics: subgroups and interactions            | Yes                       | Yes                        | Yes                       |
| 12c. Statistics: missing data                          | Yes                       | Yes                        | Yes                       |
| 12d. Statistics: loss to follow-up                     | Yes                       | Not applicable             | Yes                       |
| 12e. Statistics: sensitivity analyses                  | Yes                       | No/Unclear                 | No/Unclear                |
| Results  |                           |                            |                           |
| 13a. Participants: individual at each stage            | Yes                       | Yes                        | Yes                       |
| 13b. Participants: reasons for non-participation       | Yes                       | No/Unclear                 | Yes                       |
| 13c. Participants: flow diagram                        | Yes                       | No/Unclear                 | No/Unclear                |
| 14a. Descriptive data: characteristics of participants | Yes                       | Yes                        | Yes                       |
| 14b. Descriptive data: missing data                    | Yes                       | Yes                        | Yes                       |
| 14c. Descriptive data: follow-up                       | Yes                       | Not applicable             | Yes                       |
| 15. Outcome data                                       | Yes                       | Yes                        | Yes                       |
| 16a. Main results                                      | Yes                       | Yes                        | Yes                       |
| Discussion   |                           |                            |                           |
| 18. Key results  | Yes                       | Yes                        | Yes                       |
| 19. Limitations  | Yes                       | Yes                        | Yes                       |
| 20. Interpretation                                     | Yes                       | No/Unclear                 | No/Unclear                |
| 21. Generalisability                                   | Yes                       | No/Unclear                 | No/Unclear                |
| Other information                                      |                           |                            |                           |
| 22. Funding  | No/Unclear                | No/Unclear                 | No/Unclear                |

*Note.* The following items are not displayed in the figure as they were not applicable to the included studies: 6b, 11, 16b, 16c, 17.

## References

1. Fukuda, K.; Straus, S.E.; Hickie, I.; Sharpe, M.C.; Dobbins, J.G.; Komaroff, A. The chronic fatigue syndrome: A comprehensive approach to its definition and study. International Chronic Fatigue Syndrome Study Group. *Ann. Intern. Med.* **1994**, *121*, 953–959. [[CrossRef](#)] [[PubMed](#)]
2. Carruthers, B.M.; van de Sande, M.I.; De Meirleir, K.L.; Klimas, N.G.; Broderick, G.; Mitchell, T.; Staines, D.; Powles, A.C.P.; Speight, N.; Vallings, R.; et al. Myalgic encephalomyelitis: International Consensus Criteria. *J. Intern. Med.* **2011**, *270*, 327–338. [[CrossRef](#)] [[PubMed](#)]
3. Institute of Medicine, I.O.M. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. *Natl. Acad. Press* **2015**.
4. Prins, J.B.; van der Meer, J.W.M.; Bleijenberg, G. Chronic fatigue syndrome. *Lancet* **2006**, *367*, 346–355. [[CrossRef](#)]
5. Lowry, T.J.; Pakenham, K.I. Health-related quality of life in chronic fatigue syndrome: Predictors of physical functioning and psychological distress. *Psychol. Health Med.* **2008**, *13*, 222–238. [[CrossRef](#)]
6. de Carvalho Leite, J.C.; de L Drachler, M.; Killeth, A.; Kale, S.; Nacul, L.; McArthur, M.; Hong, C.S.; O'Driscoll, L.; Pheby, D.; Champion, P.; et al. Social support needs for equity in health and social care: A thematic analysis of experiences of people with chronic fatigue syndrome/myalgic encephalomyelitis. *Int. J. Equity Health* **2011**, *10*. [[CrossRef](#)]
7. Nacul, L.C.; Lacerda, E.M.; Champion, P.; Pheby, D.; Drachler, M.; de, L.; Leite, J.C.; Poland, F.; Howe, A.; Fayyaz, S.; et al. The functional status and well being of people with myalgic encephalomyelitis/chronic fatigue syndrome and their carers. *BMC Public Health* **2011**, *11*, 402. [[CrossRef](#)]
8. Castro-Marrero, J.; Faro, M.; Zaragoza, M.C.; Aliste, L.; de Sevilla, T.F.; Alegre, J. Unemployment and work disability in individuals with chronic fatigue syndrome/myalgic encephalomyelitis: A community-based cross-sectional study from Spain. *BMC Public Health* **2019**, *19*, 840. [[CrossRef](#)]
9. Bhatia, S.; Olczyk, N.A.; Jason, L.; Alegre, J.; Fuentes-Llanos, J.; Castro-Marrero, J. A Cross-National Comparison of Myalgic Encephalomyelitis and Chronic Fatigue Syndrome at Tertiary Care Settings from the US and Spain. *Am. J. Soc. Sci. Humanit.* **2020**, *5*, 104–115. [[CrossRef](#)]
10. Maes, M.; Twisk, F.N.M.; Johnson, C. Myalgic Encephalomyelitis (ME), Chronic Fatigue Syndrome (CFS), and Chronic Fatigue (CF) are distinguished accurately: Results of supervised learning techniques applied on clinical and inflammatory data. *Psychiatry Res.* **2012**, *200*, 754–760. [[CrossRef](#)]
11. Raine, R.; Carter, S.; Sensky, T.; Black, N. General practitioners' perceptions of chronic fatigue syndrome and beliefs about its management, compared with irritable bowel syndrome: Qualitative study. *BMJ* **2004**, *328*, 1354–1357. [[CrossRef](#)] [[PubMed](#)]
12. Nacul, L.; Lacerda, E.M.; Kingdon, C.C.; Curran, H.; Bowman, E.W. How have selection bias and disease misclassification undermined the validity of myalgic encephalomyelitis/chronic fatigue syndrome studies? *J. Health Psychol.* **2017**, 1359105317695803. [[CrossRef](#)] [[PubMed](#)]
13. LÍndal, E.; Stefánsson, J.G.; Bergmann, S.; Lindal, E.; Stefansson, J.G.; Bergmann, S. The prevalence of chronic fatigue syndrome in Iceland - A national comparison by gender drawing on four different criteria. *Nord. J. Psychiatry* **2002**, *56*, 273–277. [[CrossRef](#)] [[PubMed](#)]
14. Ranjith, G. Epidemiology of chronic fatigue syndrome. *Occup. Med.* **2005**, *55*, 13–19. [[CrossRef](#)] [[PubMed](#)]
15. Dinos, S.; Khoshaba, B.; Ashby, D.; White, P.D.; Nazroo, J.; Wessely, S.; Bhui, K.S. A systematic review of chronic fatigue, its syndromes and ethnicity: Prevalence, severity, co-morbidity and coping. *Int. J. Epidemiol.* **2009**, *38*, 1554–1570. [[CrossRef](#)] [[PubMed](#)]
16. Johnston, S.; Brenu, E.W.; Staines, D.R.; Marshall-Gradisnik, S. The adoption of chronic fatigue syndrome/myalgic encephalomyelitis case definitions to assess prevalence: A systematic review. *Ann. Epidemiol.* **2013**, *23*, 371–376. [[CrossRef](#)]
17. Brurberg, K.G.; Fønhus, M.S.; Larun, L.; Flottorp, S.; Malterud, K. Case definitions for chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME): A systematic review. *BMJ Open* **2014**, *4*. [[CrossRef](#)]
18. Lim, E.-J.; Ahn, Y.-C.; Jang, E.-S.; Lee, S.-W.; Lee, S.-H.; Son, C.-G. Systematic review and meta-analysis of the prevalence of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME). *J. Transl. Med.* **2020**, *18*, 100. [[CrossRef](#)]
19. Moher, D.; Liberati, A.; Tetzlaff, J.; Altman, D.G.; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. *BMJ* **2009**, *339*, b2535. [[CrossRef](#)]

20. Estévez-López, F.; Castro-Marrero, J.; Wang, X.; Bakken, I.J.; Ivanovs, A.; Nacul, L.; Sepúlveda, N.; Strand, E.B.; Pheby, D.; Alegre, J.; et al. Prevalence and incidence of myalgic encephalomyelitis/chronic fatigue syndrome in Europe - the Euro-epiME study from the European network EUROMENE: A protocol for a systematic review. *BMJ Open* **2018**, *8*. [[CrossRef](#)]
21. Carruthers, B.; Jain, A.K.; De Meirleir, K.L.; Peterson, D.L.; Klimas, N.G.; Lerner, A.M.; et al. Myalgic encephalomyelitis/chronic fatigue syndrome: Clinical working case definition, diagnostic and treatment protocols. *J. Chronic Fatigue Syndrome* **2003**, *11*, 7–115. [[CrossRef](#)]
22. Dowsett, E.G.G.E.; Goudsmit, E.; Macintyre, A.; Shepherd, C.B. The National Task Force on Chronic Fatigue Syndrome (CFS), Post Viral Fatigue Syndrome (PVFS), Myalgic Encephalomyelitis (ME). *Westcare* **1994**.
23. Sharpe, M.C.; Archard, L.C.; Banatvala, J.E.; Borysiewicz, L.K.; Clare, A.W.; David, A.; Edwards, R.H.; Hawton, K.E.; Lambert, H.P.; Lane, R.J. A report—chronic fatigue syndrome: Guidelines for research. *J. R. Soc. Med.* **1991**, *84*, 118–121. [[CrossRef](#)] [[PubMed](#)]
24. Munn, Z.; Moola, S.; Lisy, K.; Riitano, D.; Tufanaru, C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int. J. Evid. Based. Healthc.* **2015**, *13*, 147–153. [[CrossRef](#)] [[PubMed](#)]
25. von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P.; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: Guidelines for reporting observational studies. *Lancet* **2007**, *4*, e296. [[CrossRef](#)]
26. Nacul, L.C.; Lacerda, E.M.; Pheby, D.; Champion, P.; Molokhia, M.; Fayyaz, S.; Leite, J.C.D.C.; Poland, F.; Howe, A.; Drachler, M.L. Prevalence of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) in three regions of England: A repeated cross-sectional study in primary care. *BMC Med.* **2011**, *9*, 91. [[CrossRef](#)]
27. Rimes, K.A.; Goodman, R.; Hotopf, M.; Wessely, S.; Meltzer, H.; Chalder, T. Incidence, prognosis, and risk factors for fatigue and chronic fatigue syndrome in adolescents: A prospective community study. *Pediatrics* **2007**, *119*, e603-9. [[CrossRef](#)]
28. Lindal, E.; Stefansson, J.G.; Bergmann, S. The Prevalence of Chronic Fatigue Syndrome in Iceland—a National Comparison by Gender Drawing on Four Different Criteria. *Nord. J. Psychiatry* **2006**, *60*, 183. [[CrossRef](#)]
29. Reyes, M.; Nisenbaum, R.; Hoaglin, D.C.; Unger, E.R.; Emmons, C.; Randall, B.; Stewart, J.A.; Abbey, S.; Jones, J.F.; Gantz, N.; et al. Prevalence and incidence of chronic fatigue syndrome in Wichita, Kansas. *Arch. Intern. Med.* **2003**, *163*, 1530–1536. [[CrossRef](#)]
30. Reeves, W.C.; Jones, J.F.; Maloney, E.; Heim, C.; Hoaglin, D.C.; Boneva, R.S.; Morrissey, M.; Devlin, R. Prevalence of chronic fatigue syndrome in metropolitan, urban, and rural Georgia. *Popul. Health Metr.* **2007**, *5*. [[CrossRef](#)]
31. de Lourdes Drachler, M.; de Carvalho Leite, J.C.; Hooper, L.; Hong, C.S.; Pheby, D.; Nacul, L.; Lacerda, E.; Champion, P.; Killett, A.; McArthur, M.; et al. The expressed needs of people with chronic fatigue syndrome/myalgic encephalomyelitis: A systematic review. *BMC Public Health* **2009**, *9*, 458.
32. Martín-Martínez, E.; Martín-Martínez, M. Varied Presentation of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and the Needs for Classification and Clinician Education: A Case Series. *Clin. Ther.* **2019**, *41*, 619–624. [[CrossRef](#)] [[PubMed](#)]
33. Pheby, D.F.H.; Araja, D.; Berkis, U.; Brenna, E.; Cullinan, J.; de Korwin, J.-D.; Gitto, L.; Hughes, D.A.; Hunter, R.M.; Trepel, D.; et al. The Development of a Consistent Europe-Wide Approach to Investigating the Economic Impact of Myalgic Encephalomyelitis (ME/CFS): A Report from the European Network on ME/CFS (EUROMENE). *Healthcare* **2020**, *8*, 88. [[CrossRef](#)]
34. Fluge, Ø.; Risa, K.; Lunde, S.; Alme, K.; Rekeland, I.G.; Sapkota, D.; Kristoffersen, E.K.; Sørland, K.; Bruland, O.; Dahl, O.; et al. B-Lymphocyte Depletion in Myalgic Encephalopathy/Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment. *PLoS ONE* **2015**, *10*, e0129898. [[CrossRef](#)] [[PubMed](#)]
35. White, P.D.; Goldsmith, K.A.; Johnson, A.L.; Potts, L.; Walwyn, R.; DeCesare, J.C.; Baber, H.L.; Burgess, M.; Clark, L.V.; Cox, D.L.; et al. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): A randomised trial. *Lancet* **2011**, *377*, 823–836. [[CrossRef](#)]
36. Wearden, A.J.; Dowrick, C.; Chew-Graham, C.; Bentall, R.P.; Morriss, R.K.; Peters, S.; Riste, L.; Richardson, G.; Lovell, K.; Dunn, G.; et al. Nurse led, home based self help treatment for patients in primary care with chronic fatigue syndrome: Randomised controlled trial. *BMJ* **2010**, *340*, c1777. [[CrossRef](#)]



37. Mueller, C.; Lin, J.C.; Sheriff, S.; Maudsley, A.A.; Younger, J.W. Evidence of widespread metabolite abnormalities in Myalgic encephalomyelitis/chronic fatigue syndrome: Assessment with whole-brain magnetic resonance spectroscopy. *Brain Imaging Behav.* **2020**, *14*, 562–572. [[CrossRef](#)]
38. Maksoud, R.; du Preez, S.; Eaton-Fitch, N.; Thapaliya, K.; Barnden, L.; Cabanas, H.; Staines, D.; Marshall-Gradisnik, S. A systematic review of neurological impairments in myalgic encephalomyelitis/chronic fatigue syndrome using neuroimaging techniques. *PLoS ONE* **2020**, *15*, e0232475. [[CrossRef](#)]
39. Cockshell, S.J.; Mathias, J.L. Cognitive functioning in chronic fatigue syndrome: A meta-analysis. *Psychol. Med.* **2010**, *40*, 1253–1267. [[CrossRef](#)]
40. Chapenko, S.; Krumina, A.; Logina, I.; Rasa, S.; Chistjakovs, M.; Sultanova, A.; Viksna, L.; Murovska, M. Association of active human herpesvirus-6, -7 and parvovirus b19 infection with clinical outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome. *Adv. Virol.* **2012**, *2012*, 205085. [[CrossRef](#)]
41. Rasa-Dzelzkalēja, S.; Čapenko, S.; Krūmiņa, A.; Lin, Y.-C.; Murovska, M. Association of Human Parvovirus B19 Infection with Development and Clinical Course of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. *Proc. Latv. Acad. Sci. Sect. B Nat. Exact. Appl. Sci.* **2019**, *73*, 411–418. [[CrossRef](#)]
42. Shikova, E.; Reshkova, V.; Kumanova, A.; Raleva, S.; Alexandrova, D.; Capo, N.; Murovska, M.; European Network on ME/CFS, (EUROMENE). Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic encephalomyelitis/chronic fatigue syndrome. *J. Med. Virol.* **2020**. [[CrossRef](#)] [[PubMed](#)]
43. Nacul, L.C.; Mudie, K.; Kingdon, C.C.; Clark, T.G.; Lacerda, E.M. Hand Grip Strength as a Clinical Biomarker for ME/CFS and Disease Severity. *Front. Neurol.* **2018**, *9*. [[CrossRef](#)] [[PubMed](#)]
44. Jason, L.A.; Sunnquist, M.; Brown, A.; Furst, J.; Cid, M.; Farietta, J.; Kot, B.; Bloomer, C.; Nicholson, L.; Williams, Y.; et al. Factor Analysis of the DePaul Symptom Questionnaire: Identifying Core Domains. *J. Neurol. Neurobiol.* **2015**, *1*.
45. Lacerda, E.M.; Bowman, E.W.; Cliff, J.M.; Kingdon, C.C.; King, E.C.; Lee, J.-S.S.; Clark, T.G.; Dockrell, H.M.; Riley, E.M.; Curran, H.; et al. The UK ME/CFS Biobank for biomedical research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Sclerosis. *Open J. Bioresour.* **2017**, *4*, 4. [[CrossRef](#)]
46. Castro-Marrero, J.; Faro, M.; Aliste, L.; Saez-Francas, N.; Calvo, N.; Martinez-Martinez, A.; de Sevilla, T.F.; Alegre, J. Comorbidity in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis: A Nationwide Population-Based Cohort Study. *Psychosomatics* **2017**, *58*, 533–543. [[CrossRef](#)]
47. Shepherd, C.; Chaudhuri, A. ME/CFS/PVFS: An Exploration of the Key Clinical Issues. *Gawcott ME Assoc.* **2013**.
48. Słomko, J.; Newton, J.L.; Kujawski, S.; Tafil-Klawe, M.; Klawe, J.; Staines, D.; Marshall-Gradisnik, S.; Zalewski, P. Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: A cross-sectional study. *BMJ Open* **2019**, *9*, e023955. [[CrossRef](#)]

